Abstract: Embodiments disclosed herein describe systems and methods for deploying a new code block on a blockchain. In an embodiment, an application server may provide a user with a graphical user interface (GUI) with contract components and document components. The application server may generate an assembled contract text based on the user selecting the contract and document components. The application server may determine the blockchain addresses or local addresses of smart contract components corresponding to the contract components and the documents components. The application server may generate a code block including references to the addresses of the smart contracts and the document components or containing the executable code itself and may deploy the code block to the latest valid blockchain. The application server may execute the smart contract in the code block based in response to a digital event trigger.

Abstract: Systems and methods described herein may generate a digital payment token associated with a payor-user indicating the status of a payment obligation of the payor-user. The systems and methods may generate a first block containing the digital payment token and append the first block to a blockchain. The systems and methods may receive a confirmation message from a third-party transaction server that the payor-user has either fully or partially fulfilled his or her payment obligation. Based upon the confirmation message, the systems and methods may retrieve the block containing the digital payment token and update the digital payment token to generate an updated digital payment token. The system and methods may generate a second block containing the updated digital payment token to supersede the first block and append the second block to the blockchain. The updated digital payment token may indicate that the digital payment token has expired.

Abstract: Embodiments disclosed herein provide systems and methods for digital identity management and permission controls within distributed network nodes. A network node may receive a request to generate a new digital identity record for an entity. The network node may retrieve a template based on an entity type; and receive information, reference documents, and biometric information for the new digital identity record. The network node may associate and store the received information to the data fields in the new digital identity record, generate respective one directional cryptographic hashes of the reference documents and the biometric information, and store the hashes in the new digital identity record while storing the reference documents and biometric information in a non-blockchain repository. The network node may generate a digital identity record block for the new digital identity record, encrypt the digital identity record block, and append the encrypted block to the latest valid blockchain.

Abstract: Embodiments disclosed herein provide systems and methods for digital meeting management within a blockchain. Before a meeting, a computer may generate a digital meeting record containing a plurality of data fields and linked to various smart contracts to capture meeting activities. During the meeting, a first smart contract may authenticate and record attendees in the digital meeting record based on biometric information received from the attendees' devices. Furthermore, a second smart contract may capture in the digital meeting record, meeting actions of each attendee, including date, time, and location associated with the meeting actions. After the meeting, a third smart contract may autopopulate post meeting documentation. After review by the attendees, the third smart contract may store a hash of the documentation to the digital meeting record and store the documentation in a repository. Once appended to the blockchain, the digital meeting record becomes an immutable record of the meeting.

Abstract: The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof.

Abstract: Described are methods of treatment of cutaneous injuries or conditions comprising administration of CSE inhibitors to individuals in need thereof. Also described herein are methods of treatment of sleep-related breathing disorders comprising administration of CSE inhibitors to individuals in need thereof.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: Described herein are methods for treating chemotherapy-induced peripheral neuropathy, or human immunodeficiency virus-associated sensory neuropathy, or symptoms thereof, comprising administering to an individual in need thereof a therapeutically effective amount of a cystathionine-?-lyase (CSE) inhibitor. Also described herein are methods for using such CSE inhibitors in combination with other compounds.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: The invention relates to a method for identifying a therapeutic having analogous activity to a thiazolidinedione by contacting a cell containing a PPAR&ggr; receptor with a candidate therapeutic; and determining the level of a selected gene expression; to indicate that the candidate therapeutic is a therapeutic for treating a disease associated with a PPAR&ggr; receptor. The invention also relates to a composition comprising a plurality of selected genes or gene fragments, or a plurality of proteins or proteins fragments selected from proteins encoded by the selected genes thereof. The invention further relates to a method for determining whether a subject is responsive to treatment with a therapeutic having analogous activity to a thiazolidinedione.